Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer, with high incidence and mortality. To improve the curative effect and prolong the survival of patients, it is necessary to find new biomarkers to accurately predict the prognosis of patients and explore new s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yang, Hou, Kezuo, Wang, Yizhe, Chen, Yang, Zheng, Xueying, Qi, Jianfei, Yang, Bowen, Tang, Shiying, Han, Xu, Shi, Dongyao, Wang, Ximing, Liu, Yunpeng, Hu, Xuejun, Che, Xiaofang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264429/
https://www.ncbi.nlm.nih.gov/pubmed/34249701
http://dx.doi.org/10.3389/fonc.2021.665276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264429/
https://www.ncbi.nlm.nih.gov/pubmed/34249701
http://dx.doi.org/10.3389/fonc.2021.665276

Ejemplares similares